Relationship between patient-reported outcomes and clinical outcomes in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the ADMIRAL study

被引：0
|
作者：
Cella, D. [1 ]
Ritchie, E. [2 ]
Fabbiano, F. [3 ]
Pigneux, A. [4 ]
Kanda, Y. [5 ]
Ivanescu, C. [6 ]
Pandya, B. J. [7 ]
Shah, M. V. [7 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Weill Cornell Med, New York, NY USA
[3] Azienda Osped Osped Riuniti Villa Sofia Cervello, Palermo, Italy
[4] CHU Bordeaux, Bordeaux, France
[5] Jichi Med Univ, Shimotsuke, Tochigi, Japan
[6] IQVIA, Amsterdam, Netherlands
[7] Astellas Pharma Inc, Northbrook, IL USA
来源：
SWISS MEDICAL WEEKLY | 2020年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P9
引用
收藏
页码：15S / 15S
页数：1
相关论文
共 50 条
  • [31] Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia
    Wang, Jianxiang
    Jiang, Bin
    Li, Jian
    Liu, Ligen
    Du, Xin
    Jiang, Hao
    Hu, Jianda
    Yuan, Menghe
    Sakatani, Taishi
    Kadokura, Takeshi
    Takeuchi, Masato
    Kosako, Masanori
    Ma, Xiao
    Girshova, Larisa
    Tan, Jerome
    Bondarenko, Sergey
    Lee, Lily Wong Lee
    Khuhapinant, Archrob
    Martynova, Elena
    Hasabou, Nahla
    LEUKEMIA, 2024, 38 (11) : 2410 - 2418
  • [32] Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
    Greco, Rosa
    Imbergamo, Silvia
    Pierdomenico, Elisabetta
    Di Camillo, Barbara
    Papayannidis, Cristina
    Todisco, Elisabetta
    Borlenghi, Erika
    Fracchiolla, Nicola
    Basilico, Claudia
    Fumagalli, Monica
    Zappasodi, Patrizia
    Turrini, Mauro
    Candoni, Anna
    Lunghi, Monia
    Musso, Maurizio
    Vetro, Calogero
    Guolo, Fabio
    Mannina, Donato
    Lico, Albana
    Scattolin, Anna Maria
    Nadali, Gianpaolo
    Crugnola, Monica
    Galimberti, Sara
    Marchesi, Francesco
    Metafuni, Elisabetta
    di Toritto, Tommaso Caravita
    Minotti, Clara
    Musto, Pellegrino
    Mancini, Valentina
    Riva, Marta
    Rizzo, Lorenzo
    Grillo, Giovanni
    Cairoli, Roberto
    BLOOD, 2024, 144 : 5188 - 5189
  • [33] Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience
    Shoukier, Mahran
    Kota, Vamsi
    Kolhe, Ravindra
    Bryan, Locke J.
    Jillella, Anand P.
    Cortes, Jorge E.
    BLOOD, 2020, 136
  • [34] Quizartinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: More Patients Make It to Transplant, but Are There Any Other Benefits?
    Hunter, Bradley D.
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (02): : 99 - 100
  • [35] Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study
    Kugler, Eitan
    Cohen, Inbar
    Ram, Ron
    Canaani, Jonathan
    Amitai, Irina
    Shargian, Liat
    Nachmias, Boaz
    Krayem, Baher
    Frisch, Avraham
    Levi, Itay
    Akria, Luiza
    Raanani, Pia
    Wolach, Ofir
    Kugler, Eitan
    BLOOD, 2023, 142
  • [36] Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial
    Pandya, Bhavik J.
    Qi, Cynthia Z.
    Yang, Hongbo
    Garnham, Andy
    Shah, Manasee V.
    Zeidan, Amer M.
    BLOOD, 2020, 136
  • [37] Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial
    Zeidan, Amer M.
    Qi, Cynthia Z.
    Yang, Hongbo
    Garnham, Andy
    Shah, Manasee V.
    Pandya, Bhavik J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (03) : 762 - 764
  • [38] Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study
    Jin, Jie
    Wang, Huafeng
    Yu, Wen-Juan
    Ge, Zheng
    Wei, Xudong
    Li, Yuhua
    Jiang, Zhongxing
    Li, Yiqing
    Du, Xin
    Yang, Linhua
    Lin, Lie
    Wang, Jishi
    Yao, Yazhou
    Hu, Xiaoping
    Lan, Jianping
    Deng, Xiuzhi
    Chen, Tong
    Feng, Xianqi
    Li, Dengju
    Hou, Ming
    Fu, Rong
    Huang, Siyong
    Wang, Jingbo
    Du, Xin
    Yang, Hui
    Yang, Haiping
    Jiang, Yingzhi
    Wang, Zhijie
    Li, Deng
    Liu, Bing
    Kang, Ning
    Zhuang, Yulei
    Zhang, Yingjun
    BLOOD, 2023, 142
  • [39] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
  • [40] Pain and Opioid Use in Patients with FLT3 Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial
    Cella, David
    Ritchie, Ellen
    Pigneux, Arnaud
    Kanda, Yoshinobu
    Ivanescu, Cristina
    Pandya, Bhavik J.
    Shah, Manasee V.
    BLOOD, 2020, 136
12345